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Summary
Aims—To examine the association between relative muscle mass (RMM) and nine risk factors 
for cardiovascular disease and diabetes (CVD/DM) in U.S. youth.
Methods—We used a sample representative of the U.S. population of youth, aged 8–20 years 
(NHANES 1999–2004). We compared the prevalence of adverse levels of nine CVD/DM risk 
factors between youths in the lowest quartile of RMM and their peers in the remaining quartiles, 
controlling for age, sex, and race/ethnicity. We also examined variations in the adjusted 
prevalence of these risk factors along the entire range of RMM.
Results—The adjusted prevalence of adverse levels of risk factors among youths in the lowest 
quartile of RMM was significantly higher for seven of the nine risk factors examined compared 
with their peers in the other quartiles. Over the entire range of RMM, the adjusted prevalence of 
adverse levels of each of these seven risk factors decreased gradually with increasing RMM values 
(all p for trend <0.001).
Conclusions—RMM and prevalence of adverse risk factors for CVD/DM are highly and 
inversely associated in U.S. youth. Among youth with low RMM, the risk of these chronic 
diseases could be significantly high later in life.
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Introduction
An elevated prevalence of overweight among children and young adults is of great concern 
to the medical and public health communities because it presages an elevated prevalence of 
obesity-associated chronic conditions later in the population [1,2]. Numerous studies have 
identified typical risk factors for diabetes, atherosclerosis, heart disease and even sub-
clinical signs of these chronic conditions in obese youth. Most of these studies have used the 
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body mass index (BMI) as indicator of adiposity [3–8]. The use of BMI is widespread and 
there are age- and sex-specific BMI charts to assess overweight and obesity among children 
and youths in several populations [9]. BMI, however, reflects overall adiposity. It does not 
reflect body fat distribution or the relative contributions of fat mass and muscle mass to 
bodyweight, all of which could affect the health risks attributed to obesity in general [10,11]. 
Several studies have investigated the association between body fat distribution or body 
composition and disease risks in children and youth [12–15]. These studies have confirmed 
that central obesity and a preponderance of fat mass over muscle mass increase the risk of 
disease in this age group.
The National Health and Nutrition Examination Survey (NHANES, 1999–2004) offers the 
opportunity to examine in detail the association between body composition and health risks 
in children and adults [16]. This survey includes DXA whole body measurements for a wide 
age range of ages (8 and older) in a sample representative of the U.S. population. NHANES 
data have been used to generate reference values for body composition and a previous study 
with these data found that children and adolescents (aged 8–19 years) with a high percent 
body fat were more likely to have an adverse lipid profile than their peers with a low percent 
body fat [13].
The effect of low muscle mass enhancing the risk for insulin resistance and diabetes among 
adults has been recognized [17–19]. This is a dose-response effect: even a modest increase 
in muscle mass can diminish the risk [20,21]. However, it is not known whether this relation 
would be consistently found outside the adult population. We designed this study to test the 
association between low relative muscle mass (RMM) and a panel of nine measurements 
related to the risk for cardiovascular disease (CVD) and diabetes mellitus (DM) in U.S. 
youth, aged 8–20 years. We also examined the association between RMM and these risk 
factors along the entire range of RMM.
Methods
Survey
The sample was obtained from the NHANES, conducted by the National Center for Health 
Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC) [16]. NHANES 
is a complex, multistage probability sample of the U.S. civilian non-institutionalized 
population. This survey includes data from interviews and physical and laboratory 
examinations. The period included in the study was 1999–2004, during which Non-Hispanic 
blacks, Mexican Americans, adolescents (aged 12–19 years), and people aged ≥60 years 
were oversampled. The survey was approved by NCHS Institutional Review Board. Written 
consent was obtained for participants aged ≥18 years, and parental consent was obtained for 
youths aged 7–17 years.
Study population
The study population was restricted to youths aged 8–20 years for the 6-year period selected. 
Of interest for this study was that the data for this period included body composition 
measurements performed with dual-energy X-ray absorptiometry (DXA) among individuals 
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aged 8 years and older. Approximately 21% of NHANES participants for the period of this 
study had one or more DXA values missing. People with valid missing values included 
pregnant women, subjects who weighted over 300 pounds or were taller than 6 ft 5 in. The 
selected age group included 9751 individuals. The sample for analysis was reduced to 7321 
individuals after excluding individuals other than non-Hispanic white, non-Hispanic black, 
or Mexican American (n = 807); and individuals with no measurement of DXA (n = 1623). 
Fasting values for LDL-C, triglycerides, glucose, and insulin were available in a subsample 
aged ≥12 years and fasted between8.5 and 23 h overnight. Thus, the sample size for 
measurements that required overnight fasting (morning sample) was reduced even further 
(range: 2273–2643).
DXA measurements
The elements of body composition used in this study were lean tissue mass without bone 
(muscle mass) and fat mass. The missing DXA data of eligible participants were imputed 
and five sets of DXA values were generated for analysis [16]. We performed each analysis 
five times, one for each set of imputed DXA values, to obtain the mean estimate for RMM 
and its adjusted standard error (SE) in the analysis as recommended [16].
Definition of adverse levels of risk factors and relative muscle mass
The panel of nine variables selected for this study, which were considered risk factors for 
CVD/DM, includes C-reactive protein (CRP), diastolic blood pressure (DBP), systolic blood 
pressure (SBP), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), serum triglycerides, plasma glucose, and insulin. 
LDL-C was derived from Friedewald’s equation LDL-C = (TC) − (HDL-C) − 
(Triglycerides/5) [22]. To define an adverse level of a risk factor, we divided our sample 
into three age groups (8–11, 12–15, and 16–20 years), and within each age group and sex we 
divided the distribution of each of the nine risk-defining variables into quartiles. We 
considered the individuals at the top quartile of each variable (bottom quartile for HDL-C) 
as being in the adverse risk category. Unlike the case of adults, among youths there are no 
thresholds for risk factors that reliably predict CVD/DM later in life. Cutoffs for metabolic 
and blood pressure risk in children are commonly based on their location along the 
percentile distribution of the variable of interest. This is done not much for clinical reasons 
but for epidemiological reasons: children tend to maintain their percentile ranking as they 
age [23,24].
We defined RMM as the percentage of muscle mass relative to the sum of muscle and fat 
mass (i.e., 100 × muscle mass (kg)/(muscle mass (kg) + fat mass (kg))), a measure of the 
contribution of relative muscle mass to body composition. This is a variation of a measure 
introduced recently [25]. To rank the subjects according to RMM we distributed them into 
quartiles. The cutoffs for these quartiles were, from lowest to highest, ≤64.2%, 64.3–70.9%, 
71.0–77.4%, and ≥77.5%.
Statistical analyses
To obtain unbiased national estimates and proper standard errors (SE) of estimates due to 
the complex probability sample of NHANES, sample weights and the cluster design were 
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considered in all analyses [16]. For analyses that required fasting values of risk factors 
(LDL-C, triglycerides, glucose, and insulin) we used the morning sample weights. For 
analyses involving the other risk factors, we used the examination sample weights. To 
compare the prevalence of individuals with adverse levels of each risk factor between the 
lowest quartile and the remaining quartiles of RMM, we used multiple logistic regressions 
controlling for age group, sex, and race/ethnicity. To further investigate the association 
between adverse levels of risk factors and RMM along the entire range of RMM, we also 
used multiple logistic regressions treating the four quartiles of RMM as an independent, 
continuous variable in the model. All data analyses were done in SAS version 9.3 using 
complex survey analysis procedures [26].
Results
To test for possible bias in our sample, we compared included and excluded individuals. The 
excluded group included more women than the included group (p < 0.001). This difference 
is probably because DXA measurements were not performed on women whose pregnancy 
status was positive or uncertain. Regarding the nine risk factors included in this study, there 
were statistically significant differences in the mean values of SBP, HDL-C, triglycerides, 
and fasting insulin between included and excluded (all p < 0.01); but the absolute 
differences were minor and probably have not clinical relevance.
Table 1 shows the percent distribution by age group, sex, and race/ethnicity and the mean 
value (±SE) of each variable of our panel of risk factors across quartiles of RMM in our 
study population. About 61% of this population was aged 15 years or younger. This 
percentage peaks at about 70% in the third quartile and reaches a minimum of about 53%in 
the upper quartile of RMM. Approximately 58%of our study population was male but this 
percentage varies from 31% in the first quartile to 95.2% in the top quartile of RMM. 
Regarding race/ethnicity, 70.2% of the study population was non-Hispanic white, 16.8% 
was non-Hispanic black, and the rest was Mexican American. The total sample size having 
DXA values was 7321 but the sample size used for the analyses of the nine risk factors 
ranged from4158 to 6674 for the non-fasting samples and from 2273 to 2643 for the fasting 
subsample. Table 1 shows that as RMM increases, the mean for most risk factors decreases 
(increases for HDL-C). The means for DBP and glucose change little across quartiles of 
RMM.
The cutoffs that we used to define adverse levels of risk factors are presented in Table 2. 
Overall, these cutoffs increased with age (decreased for HDL-C). Table 3 shows that, 
independently of age group, sex, and race/ethnicity, the prevalence of adverse levels for all 
seven risk factors (except for DBP and fasting glucose) is statistically significantly greater 
among youths in the lowest quartile of RMM than among their peers in the other quartiles. 
In the lowest quartile of RMM, the risk factor with the lowest prevalence was adverse DBP 
(31.0%) and the one with the highest prevalence was adverse CRP (51.5%). In contrast, the 
risk factor with the lowest prevalence in the rest of the quartiles was adverse fasting insulin 
(15.9%) and the one with the highest prevalence was adverse DBP (29.0%).
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Table 4 presents the adjusted odds ratio of having an adverse level of each risk factor for 
each quartile increase of RMM according to the fitted model. In this case, except for DBP 
and fasting glucose, there is a statistically significant reduction in the odds of having an 
adverse level for all risk factors for each step increase across quartiles of RMM. The largest 
reduction in odds occurs for fasting insulin: for each quartile above the bottom quartile of 
RMM there is a reduction of about 68% in the odds of having an adverse fasting level of this 
hormone.
Fig. 1 illustrates the adjusted prevalence of nine adverse risk factors across quartiles of 
RMM. This figure clearly shows that in most cases the prevalence of an adverse risk factor 
steadily decreases as RMM increases. This decreasing trend in prevalence was particularly 
sharp for adverse levels of CRP and fasting insulin and almost non-existent for adverse 
levels of DBP.
Discussion
Among U.S. youth, aged 8–20 years, we have examined and quantified the association 
between RMM and metabolic risk factors. First, our analyses show that for the nine 
CVD/DM risk factors included in this study, the prevalence of adverse levels among youths 
in the lowest quartile of RMM is higher than the prevalence among their peers in the other 
quartiles of RMM. In two cases (CRP and fasting insulin) the prevalence of adverse levels 
of risk factors is both about 3.1 times higher in the lowest quartile of RMM group than in the 
remaining quartiles combined. Second, our analysis shows that the inverse association 
between RMM and the prevalence of adverse levels of CVD and DM risk factors is graded. 
With the exception of adverse DBP and adverse fasting glucose, the odds of having an 
adverse level of any of the other seven risk factors gradually diminish as RMM increases. 
The reduction of the odds of having an adverse level of a risk factor for each full quartile 
increase of percentage RMM ranged from 32% for adverse SBP to 68% for adverse fasting 
insulin.
Results similar to ours have been reported in previous studies among adults. A recent study 
(n = 13,644 adults aged >20 years from the NHANESIII) found that a skeletal muscle index 
(SMI: muscle mass, measured with bioimpedance, relative to body weight) is inversely 
related to both insulin resistance and the risk of pre-diabetes [27]. A 10% increase of SMI 
was associated with an 11% reduction in the indicator of insulin resistance and a12% 
reduction in the prevalence of pre-diabetes. A separate study [17] with the same population 
has reported that sarcopenia (SMI more than two standard deviations below the sex specific 
mean in adults aged 18–39 years) was strongly associated with insulin resistance, 
particularly among the obese younger than 60 years. A study among Australian men (n = 
1195 adults aged 35–81 years) concluded that high levels of fasting insulin, low muscle 
mass (measured with DXA scans) were independently associated with the presence of the 
metabolic syndrome [18], a clustering of individual risk factors for CVD/DM with not yet 
known pathophysiological mechanism [28].
Basically, our study shows that the graded, inverse association between percent muscle mass 
and metabolic risk observed in adults is also present with noticeable strength among youths 
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aged20 years or younger. Our results, generated with reliable measurements of muscle mass 
and risk factors, are applicable to the U.S. population in this age range.
Population-based studies of body composition and risk for chronic conditions in children 
and young adults are scarce and they have emphasized the fat content over the muscle 
content as a risk factor for chronic conditions. A recent study involving two large samples of 
(n = 12,279 U.S. children and youth aged 6–18 years from NHANES) reported that percent 
body fat is strongly associated with the prevalence of individuals with adverse levels (5th 
quartile) of seven risk factors in boys and girls [12]. These results, however, are not 
generalizable to the U.S. population because the authors did not use sampling weights to 
compensate for the complex sampling scheme of the NHANES.
In summary, we have demonstrated that the association between RMM and the prevalence 
of risk factors for CVD/DM, proven to be strong among adults, is also strong among U.S. 
boys. A testable prediction from our study is that boys affected by diseases that compromise 
muscle mass, such as muscular dystrophy, could be at much higher risk for CVD/DM than 
their unaffected peers. For example, the average RMM measured by magnetic resonance in a 
small sample of 9 boys, aged 6–12, with Duchenne Muscular Dystrophy, was 41% (range: 
11.5–66.7%) [29]. This average is well below the average for the lowest quartile of our 
sample, 58.4% (range: 41.3–64.2%).
Our study has several limitations: first, though DXA has been used as a precise tool 
measuring body composition, it is known than the lean soft tissue mass as measured by 
DXA is an overestimate of muscle mass [30]; second, the (weighted) T-test revealed that 
RMM of those who fasted was different (p < 0.01) from the RMM of those who did not. 
Thus, the results involving fasting values might not be generalizable; third, the cutoff points 
that we used to define adverse levels of risk factors were arbitrary (quartiles) and other 
cutoffs might show a different relationship with RMM. However, we tested other cutoffs, 
such as quintiles or tertiles, and they yielded similar results (data not shown); fourth, the 
observed relationship between low RMM and adverse risk factors might be mediated by fat 
mass. With our approach, we cannot separate one effect from the other, but the focus of our 
study was to examine the metabolic risks associated with low RMM. In our opinion, given 
the consistency of our study with the results reported in previous studies, these limitations 
do not invalidate our results.
In conclusion, our study has shown that, in the U.S. population, adverse levels of risk factors 
related to CVD/DM are more prevalent among youths, aged 8–20 years, with low RMM 
than among their peers with greater RMM.
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Adjusted prevalence (%) of nine adverse risk factors across quartiles of relative muscle mass 
(RMM), adjusting for age group, sex, and race/ethnicity. The quartiles of RMM were treated 
as a continuous variable with a range from1 to 4. Their cut-off values were 1: ≤64.2%; 2: 
64.3–70.9%; 3: 71.0–77.4%; 4: ≥77.5%.
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Table 2
Cutoffs used to define abnormal levels of risk factors by age and sex. Each cutoff is the threshold between the 
third and fourth quartile (first and second quartile for adverse HDL-C levels).
Sex Risk factor Age group
8–11 years 12–15 years 16–20 years
Male DBP (mmHg) ≥61.8 ≥65.2 ≥71.4
SBP (mmHg) ≥108.1 ≥115.5 ≥122.1
CRP (mg/dl) ≥0.107 ≥0.097 ≥0.137
TC (mg/dl) ≥182.2 ≥178.5 ≥177.4
HDL-C (mg/dl) <42.1 <40.1 <36.9
LDL-C (mg/dl)a ≥107.9 ≥110.9
Triglycerides (mg/dl)a ≥108.5 ≥121.5
Glucose (mg/dl)a ≥97.9 ≥97.2
Insulin (µU/ml)a ≥14.1 ≥13.3
Female DBP (mmHg) ≥62.9 ≥67.9 ≥69.6
SBP (mmHg) ≥107.2 ≥111.2 ≥113
CRP (mg/dl) ≥0.115 ≥0.088 ≥0.313
TC (mg/dl) ≥185.7 ≥177.3 ≥189.2
HDL-C (mg/dl) <42.3 <42.1 <42.2
LDL-C (mg/dl)a ≥104 ≥113.5
Triglycerides (mg/dl)a ≥103.9 ≥112.9
Glucose (mg/dl)a ≥93.8 ≥92.2
Insulin (µU/ml)a ≥15.8 ≥14
See list of abbreviations in footnote to Table 1.
a
Fasting subsample.
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Table 3
Adjusted prevalence (%) of youth aged 8–20 years with an adverse levela of a CVD/DM risk factor according 
to quartile of RMM: lowest (≤64.2%) and the rest (>64.2%), adjusted for age group, sex, and race/ethnicity; 
NHANES 1999–2004.





DBP 31.0 29.0 0.421
SBP 38.1 23.6 <0.001
CRP 51.5 16.6 <0.001
TC 31.6 23.0 <0.001
HDL-C 45.4 23.7 <0.001
LDL-Cb 31.3 24.4 0.002
Triglyceridesb 43.2 24.4 <0.001
Glucoseb 34.0 27.6 0.054
Insulinb 48.5 15.9 <0.001
See list of abbreviations in footnote to Table 1.
a
Adverse level is defined as being in the upper quartile (lowest quartile for HDL-C) of the age group and sex specific distribution of the risk factor.
b
Fasting subsample.
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Table 4
Odds ratio (95% confidence interval, CI) of having an adverse levela of a risk factor for each quartile increase 
of relative muscle mass among youth, aged 8–20 years, controlling for age group, sex, and race/ethnicity; 
NHANES 1999–2004.
Adverse level of CVD/DM risk factor Odds ratio (95% CI) p value for trend
DBP 0.97 (0.89, 1.05) 0.450
SBP 0.68 (0.64, 0.74) <0.001
CRP 0.39 (0.36, 0.43) <0.001
TC 0.74 (0.70, 0.79) <0.001
HDL-C 0.55 (0.49, 0.61) <0.001
LDL-Cb 0.67 (0.61, 0.75) <0.001
Triglyceridesb 0.56 (0.49, 0.64) <0.001
Glucoseb 0.93 (0.80, 1.07) 0.294
Insulinb 0.32 (0.26, 0.40) <0.001
See list of abbreviations in footnote to Table 1.
a
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